Luyendijk, Marianne http://orcid.org/0000-0002-9552-2877
Jager, Agnes http://orcid.org/0000-0002-7713-1450
Buijs, Sanne M. http://orcid.org/0000-0003-0548-1803
Siesling, Sabine http://orcid.org/0000-0002-0273-824X
Groot, Carin A. Uyl-de http://orcid.org/0000-0001-6492-5203
Blommestein, Hedwig M. http://orcid.org/0000-0002-5846-0531
Article History
Accepted: 25 April 2023
First Online: 28 May 2023
Declarations
:
: No funding was acquired for this study.
: M. Luyendijk, S.M. Buijs, S. Siesling have no conflicts of interest to declare. A. Jager reports an unrestricted grant received from Agendia<sup>®</sup> (MammaPrint<sup>®</sup>) to set up a database with genomic data (obtained with MammaPrint<sup>®</sup>) with the objective to discover new prognostic molecular markers within early stage breast cancer patients. Note: no restrictions were imposed on the use of the grant paid to the institute. Dr Blommestein reports a fee for participation in an advisory board from Pfizer, paid to the institute. C.A. Uyl-de Groot reports grants from Boehringer Ingelheim, Astellas, Celgene, Sanofi, Jansen-Cilag, Bayer, Amgen, Genzyme, Merck, Gilead, Novartis, AstraZeneca, Roche, all payments to the institute.
: The TOTAM study, from which we used patient-level data, was approved by the Local Ethics Committee (Erasmus MC, Rotterdam; MEC 17-548) and was registered at the Dutch Trial Registry (NL6918).
: All patients participating in the TOTAM study gave their written informed consent for the study and also to use their data for other (related) research.
: Not applicable.
: The model is available on request.
: HB, AJ, ML contributed to the development of the study design. HB, AJ, ML, SB contributed to the data collection and data analyses. All authors contributed to the critical revision of the manuscript. All authors read and agreed with the final version of the manuscript.